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TX-004HR vaginal estradiol has negligible to very low systemic
absorption of estradiol
David F. Archer, MD,1 Ginger D. Constantine, MD,2 James A. Simon, MD,3
Harvey Kushner, PhD,4 Philip Mayer, PhD,5 Brian Bernick, MD,6 Shelli Graham, PhD,6 and
Sebastian Mirkin, MD,6 on behalf of the REJOICE Study Group
Abstract
Objective: To evaluate the pharmacokinetics of TX-004HR vaginal estradiol softgel capsules when used
for treating moderate-to-severe dyspareunia in postmenopausal women with vulvar and vaginal atrophy.
Methods: A substudy of the REJOICE trial (multicenter, double-blind, placebo-controlled, phase 3) evaluated
the pharmacokinetics of 4, 10, and 25-mg TX-004HR doses once/d for 2 weeks, followed by twice/wk for 10 weeks.
Serum samples obtained at 2, 4, 6, 10, and 24 hours postdose on days 1 and 14, and once on day 84, were analyzed
for area under the serum concentration-time curve, tmax, Cmin, Cavg, and Cmax for estradiol, estrone, and
estrone conjugates.
Results: Seventy-two women (mean 59 y) participated. TX-004HR 4 mg showed no statistical differences from
placebo in estradiol pharmacokinetic (PK) parameters. At 10 mg, estradiol Cmax was statistically higher than placebo
on day 1, but was not different from placebo on day 14. With 25 mg, estradiol PK parameters were statistically higher
than placebo. Estradiol Cavg values for 25 mg were 9.1 pg/mL on day 1 and 7.1 pg/mL on day 14. Estrone and estrone
conjugate PK parameters with TX-004HR were lower than or similar to placebo across all doses. No drug
accumulation was observed.
Conclusions: Vaginal TX-004HR resulted in negligible to very low systemic absorption of estradiol. No statistical
differences in estradiol PK parameters were observed on day 14 with 4 and 10 mg, and only minor increases were
observed with 25 mg (within the normal postmenopausal range). This PK substudy, in conjunction with the primary
efficacy results, demonstrated that TX-004HR provided local benefits of estradiol with limited systemic exposure.
Key Words: Estradiol – Estrogen therapy – Menopause – Pharmacokinetics – TX-004HR – Vaginal
atrophy.
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L

ow-dose vaginal estrogen is a safe and effective
treatment for symptoms associated with vulvar and
vaginal atrophy (VVA), such as vaginal dryness,
irritation, and pain with intercourse, which occur as a
result of declining estrogen associated with menopause.1,2
The rationale for using a vaginal delivery system includes
the ability to provide low doses of estrogen with local
administration to eliminate or minimize levels of circulating
estrogens,1,3 and bypass hepatic circulation, thus reducing
potential side effects.4
The Working Group on Women’s Health and Well-Being
in Menopause petitioned the US Food and Drug Administration (FDA) to modify the labeling of low-dose vaginal
estrogens, which do not significantly increase systemic levels
of estradiol. The US FDA held a workshop on November 10,
2015, in which they invited a panel of scientific experts to
discuss the topic of product labeling for local estrogen
therapies.5 Some concerns remain regarding elevations in
circulating estrogen concentrations with some vaginal products,6 despite the well-characterized and positive benefit/risk
ratio of low-dose vaginal estrogen products.
TX-004HR (TherapeuticsMD, Inc., Boca Raton, FL) is a
new 17b-estradiol vaginal product developed to rapidly and
effectively treat menopausal VVA signs and symptoms with
no systemic exposure. Its novel design does not require an
applicator, intended to make it easy to use and increase user
acceptability and overall satisfaction.
Phase 1 pharmacokinetic (PK) studies have shown that
women using 10 or 25-mg doses of TX-004HR have very low
levels of serum estradiol after administration, which were
within the postmenopausal range.7 Furthermore, these same
women had estrogen levels that were approximately 30% of
the serum estrogen concentrations observed in women who
received identical doses of an approved vaginal estradiol
tablet after 24 hours.7
The REJOICE trial demonstrated that TX-004HR (4, 10,
and 25 mg) was safe, well-tolerated, and effective for treating
symptomatic VVA. Women who were treated with any
TX-004HR dose had significant improvements in percentages
of vaginal superficial and parabasal cells, vaginal pH,
and severity of dyspareunia as early as 2 weeks, and vaginal
dryness as early as 6 weeks, relative to women treated
with placebo, with improvements continuing to 12 weeks.8
The objective of this study was to evaluate the pharmacokinetic profile after the daily vaginal administration of
3 doses of TX-004HR (4, 10, and 25 mg) for 2 weeks and
then at day 84 to assess systemic exposure of estradiol and
its metabolites.

women (NCT02253173). The REJOICE trial was conducted
at 89 sites in the United States and Canada from October 2014
to October 2015, and assessed the four co-primary endpoints
of changes from baseline to week 12 in the percentages of
vaginal superficial and parabasal cells, vaginal pH, and the
severity of dyspareunia compared with placebo.8
Women were randomized to the PK substudy separately
from the main phase 3 study participants using a computergenerated system based on block sizes of four, and a ratio of
1:1:1:1 to either 4, 10, or 25 mg TX-004HR, or matching
placebo. Women self-administered one vaginal capsule daily
for 2 weeks, followed by 10 weeks of twice-weekly dosing.
The appearance and packaging of TX-004HR and placebo
were identical to facilitate double-blinding of the study
participants and all those involved in the conduct of the study
(site staff, clinical research associates, sponsor representatives). Double-blinding was to be broken only in emergency
situations and was to be sustained through database lock. The
protocol and informed consent form were approved by an
independent institutional review board. The trial was conducted in accordance with applicable laws and regulations
including the International Conference on Harmonization
Guideline for Good Clinical Practice and the Declaration
of Helsinki.

METHODS

Study endpoints
The PK substudy of the REJOICE trial was designed to
assess hormone concentrations of estradiol, estrone, and
estrone conjugates at screening, and at days 1, 14, and 84
of treatment in a subset of participants. Serum samples were
analyzed to characterize the following PK parameters from
0 to 24 hours: area under the serum concentration-time curve

Study design
The PK substudy was part of the REJOICE trial—a large,
multicenter, double-blind, randomized, placebo-controlled
phase 3 trial evaluating the efficacy and safety of the investigational drug, TX-004HR (4, 10, and 25 mg), for the treatment of dyspareunia associated with VVA in postmenopausal

2
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Study participants
Participants provided written informed consent before any
study-related activities. Healthy postmenopausal women 40
to 75 years of age were included if they had 5% superficial
cells on vaginal cytological smear; vaginal pH >5.0; a most
bothersome symptom of moderate-to-severe vaginal pain
associated with sexual activity (dyspareunia); onset of
moderate-to-severe dyspareunia during postmenopause; body
mass index (BMI) 38 kg/m2; and anticipated having sexual
activity (with vaginal penetration) during the trial period.
Main exclusion criteria included use of oral estrogen, progestin, androgen, or selective estrogen receptor modulatorcontaining products within 8 weeks; transdermal hormones
within 4 weeks; vaginal hormones (rings, creams, gels) within
4 weeks; intrauterine progestins within 8 weeks; progestin
implants/injectables or estrogen pellets/injectables within
6 months; vaginal lubricants or moisturizers within 7 days
before vaginal pH assessment during screening; investigational drugs within 60 days; or an intrauterine device within
12 weeks. Concomitant medications were allowed, with the
exception of the above excluded medications, and recorded
in diaries. Participants who had used hormone therapies
underwent a washout period.
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(AUC, by the trapezoidal rule), average concentration (Cavg,
AUC/dosing interval), peak concentration (Cmax), minimum
concentration (Cmin), and time to maximum concentration
(tmax) for each hormone on days 1 and 14. Accumulation
ratios (day 14/day 1) were calculated for AUC and Cmax.
Mean serum estradiol concentrations were calculated for
samples collected on day 84, approximately 4 days after
the last insertion of TX-004HR, to determine the trough value
of estradiol after chronic treatment where the product was
given twice weekly.
Time 0 hour serum samples were obtained at screening, and
at day 1 and day 14 before dosing. Baseline values were
characterized by averaging the two pretreatment samples
(screening and day 1). After women self-administered treatments, serum samples were taken at five postdose time points
(2, 4, 6, 10, and 24 h) on days 1 and 14, and one final sample at
approximately day 84. Sex hormone binding globulin
(SHBG) measurements were obtained before treatment on
days 1 and 14, and at the final hormone blood draw on day 84.
Analytical methods
The bioanalysis was performed at InVentiv Clinical
Laboratories, Inc. (Princeton, NJ). Serum samples were analyzed for estradiol, estrone, and estrone conjugates using gas
chromatography/tandem mass spectrometry (GC/MS/MS).
Estradiol and estrone were extracted from 0.400 mL of human
serum by a solid-phase extraction procedure. Separately,
estrone conjugates were also extracted from 0.400 mL of
human serum by a solid-phase extraction procedure that
selectively eluted the conjugates and retained estrone. The
eluates were then subjected to a hydrolysis step to convert the
estrone conjugates to estrone. All compounds were detected
and quantified by tandem mass spectrometry in negative ion
mode on a Finnigan TSQ-700 mass spectrometer equipped
with a Varian GC and Leap CTC A200S autosampler. Calibration curves were obtained by performing linear regression
(weighted 1/x2) on the calibration standards. Within-run and
between-run coefficients of variation for accuracy and precision for estradiol, estrone, and estrone conjugates were
within the US FDA-allowable limits, which were 20% for
the lower limit of quantification (LLOQ) and 15% for all other
quality control (QC) samples. Accuracy (bias), as reported
below, is defined as the closeness of the mean test results
obtained by the assay to the actual value (concentration) of the
analyte, and precision is defined as the closeness of individual
measure of an analyte when the procedure is applied repeatedly
to multiple aliquots of a single homogeneous serum sample.
Estradiol
Calibration standards for estradiol were prepared in water
fresh each day. Validation QC samples were prepared for
estradiol at five target concentrations (2.00, 6.52, 51.5, 441,
and 3216 pg/mL), which spanned the calibration range of
the assay. The LLOQ QC samples were prepared in water.
All other QC samples were prepared in charcoal-stripped
human serum by spiking above the endogenous levels to

approximately the target nominal concentrations. The true
concentrations of the serum samples were calculated from the
mean value of all valid measurements obtained for each level.
The validated concentration range for estradiol was 2.00 to
500 pg/mL. The coefficient of variation for estradiol standards
was 7.30% for between-run precision and the bias was
2.00% to 3.80% for between-run accuracy. Sensitivities
for estradiol were 4.83% for precision and 8.00% for
accuracy for the LLOQ samples. The within-run and
between-run coefficients of variation for estradiol for other
QC samples were within allowable limits for accuracy
(9.97% to 5.45%) and precision (8.46%). The specificity
and selectivity of the method were also verified against
endogenous matrix components. The average recovery of
estradiol from charcoal-stripped human serum was 75.3%,
and the average recovery of internal standard was 73.9%.
Estrone
Calibration standards for estrone were prepared in water
fresh each day. Validation QC samples were prepared for
estrone at five target concentrations (5.00, 17.1, 120, 865, and
6176 pg/mL), which spanned the calibration range of the
assay. The LLOQ QC samples were prepared in water. All
other QC samples were prepared in charcoal-stripped human
serum by spiking above the endogenous levels to approximately the target nominal concentrations. The true concentrations of the serum samples were calculated from the mean
value of all valid measurements obtained for each level.
The validated concentration range for estrone was 5.00 to
1000 pg/mL. The coefficient of variation for estrone standards
was 6.37% for between-run precision and the bias was
3.20% to 4.00% for between-run accuracy. Sensitivities
for estrone were 13.2% for precision and 20.0% for accuracy
for the LLOQ samples. The within-run and between-run
coefficients of variation for estrone for other QC samples
were within allowable limits for accuracy (7.41% to 14.1%)
and precision (9.33%). The specificity and selectivity of the
method were also verified against endogenous matrix components. The average recovery of estrone from charcoalstripped human serum was 73.4%, and the average recovery
of internal standard was 73.5%.
Estrone conjugates
The bioanalytical method measured total estrone conjugates via a hydrolysis step; however, the standard curve was
prepared with estrone sulfate, the only conjugate that is
commercially available. Final concentrations included all
hydrolyzed estrone conjugates (glucuronides and sulfates),
which were quantified against hydrolyzed estrone sulfate
standards. Calibration standards were prepared in water fresh
each day. Validation QC samples were prepared at six target
concentrations (25.0, 75.0, 525, 3750, and 5000 pg/mL),
which spanned the calibration range of the assay, and
25,000 pg/mL, which was used to verify dilution samples
with concentrations above the calibration range. The LLOQ
QC samples were prepared in water due to high endogenous
Menopause, Vol. 24, No. 5, 2017
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levels observed in the matrix. All other QC samples were
prepared in unaltered or noncharcoal-stripped human serum
by spiking above the endogenous levels to approximately the
target nominal concentrations. The true concentrations of the
serum samples were calculated from the mean value of all
valid measurements obtained for each level.
The validated concentration range for estrone conjugates
was 25.0 to 5000 pg/mL. The coefficients of variation for
estrone sulfate standards were 6.62% for between-run precision and the bias was 3.20% to 3.20% for between-run
accuracy. Sensitivities for estrone conjugates were 5.88% for
precision and 4.00% for accuracy for the LLOQ samples.
The within-run and between-run coefficients of variation for
estrone conjugates for other QC samples were within allowable limits for accuracy (13.1% to 3.54%) and precision
(4.51%).
Statistical analyses
For pharmacokinetic analyses, data from participants were
included if they had completed the study, were at least 80%
compliant with the treatment, had measurements for all coprimary efficacy endpoints, had no significant protocol violations, and had sufficient blood samples for PK analyses.
Descriptive and inferential statistical analyses were performed using SAS v.9.2. All statistical tests were two-sided.
Baseline and demographic variables were descriptively summarized by treatment group. T tests were used to determine
significant differences between TX-004HR doses and placebo
for PK parameters.
Because estradiol, estrone, and estrone conjugates are
present in women as endogenous compounds, the PK
analyses determined PK parameters as ‘‘unadjusted for baseline’’ and ‘‘baseline-adjusted’’ values. Baseline estrogen
values for each participant were determined. Sample values
estimated as below the limit of quantification were replaced
by the LLOQ for that analyte, as determined during the
method validation (estradiol 2.0 pg/mL, estrone 5.0 pg/mL,
and estrone conjugates 25.0 pg/mL). For unadjusted AUC
and Cavg calculations, the concentration at time 0 was set
to 0.0 pg/mL.

RESULTS
Participant disposition and baseline characteristics
Of the 764 women randomized to treatment in the main
trial, 72 participants at 11 centers qualified for and agreed
to participate in the PK substudy. These 72 women were
randomized to TX-004HR 4 mg (n ¼ 18), 10 mg (n ¼ 19),
25 mg (n ¼ 18), or placebo (n ¼ 17). One participant in the
placebo group discontinued due to an adverse event
(emotional liability). Overall, 97.2% of the women were
compliant (80% vaginal tablets) with dosing based on
diary data.
Participants had a mean age of 59 years and a mean BMI of
28 kg/m2; the majority (94%) were white (Table 1).
Pharmacokinetics results
Estradiol
Mean serum estradiol concentrations by time for each
dose are shown in Figures 1 to 3. Mean baseline values were
5.0 pg/mL for all groups and ranged from 2.0 to 15.7 pg/mL
for individuals. Estradiol concentrations on day 84 were
similar to baseline and placebo for TX-004HR 4, 10, and
25-mg dose groups.
No statistical differences were observed between TX004HR 4 mg and placebo in any of the unadjusted estradiol
measures of AUC, Cmax, Cavg, Cmin, and tmax (Table 2).
TX-004HR 10-mg dose, AUC, and Cavg were not different
than with placebo. Cmax values were higher than placebo
(mean of 10.9 pg/mL for 10 mg vs 6.6 pg/mL for placebo) on
day 1, but were not significantly different from placebo on day
14 (Table 2).
With the 25-mg dose, estradiol AUC, Cmax, and Cavg were
statistically different from placebo at days 1 and 14 (Table 2).
Estradiol average concentrations for the 25-mg dose were 9.1
and 7.1 pg/mL on days 1 and 14, respectively. Overall, AUC
values were lower at day 14 than day 1 for all groups. No
significant differences were observed in overall mean AUC
and Cmax, ratios (day 14-day 1) between each group and
placebo. Baseline-adjusted results for estradiol were similar to
the unadjusted results (Supplemental Table S1, Supplemental
Digital Content 1, http://links.lww.com/MENO/A205).

TABLE 1. Participant demographics and baseline characteristics
Characteristics
Age, y
Race, n (%)
White
Black or African American
BMI, kg/m2
Smoking history, n (%)
No
Yes
Years of smoking
Baseline hormone values, pg/mL
Estradiol
Estrone
Estrone conjugates

TX-004HR 4 mg (n ¼ 18)

TX-004HR 10 mg (n ¼ 19)

TX-004HR 25 mg (n ¼ 18)

Placebo (n ¼ 17)

57.4  7.1

58.5  7.1

59.2  6.4

58.9  6.1

18 (100)
0 (0)
28.3  5.6

18 (94.7)
1 (5.3)
28.2  4.5

16 (88.9)
2 (11.1)
28.9  5.3

16 (94.1)
1 (5.9)
27.2  5.5

12 (66.7)
6 (33.3)
33.2  12.0

6 (31.6)
13 (68.4)
21.8  11.2

12 (66.7)
6 (33.3)
23.8  15.8

10 (58.8)
7 (41.2)
21.9  12.4

3.9  2.4
15.3  4.8
237.7  180.8

4.9  3.4
20.3  8.6
239.2  174.2

3.6  1.7
16.7  7.8
343.4  421.1

4.5  2.6
19.4  8.8
275.9  152.6

Data represented as mean  SD unless stated otherwise.
BMI, body mass index.
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FIG. 1. Unadjusted mean serum estradiol concentrations TX-004HR
4 mg (n ¼ 18) versus placebo (n ¼ 17).

FIG. 3. Unadjusted mean serum estradiol concentrations TX-004HR
25 mg (n ¼ 18) versus placebo (n ¼ 17).

Estrone and estrone conjugates
Mean baseline estrone concentrations ranged from 15.3 to
20.3 pg/mL for all groups. No values were significantly higher
for TX-004HR 4, 10, and 25-mg doses versus placebo for any
of the unadjusted estrone AUC, Cmax, Cavg, Cmin, and tmax
on days 1 and 14, except on day 14 tmax for the 25-mg dose
(Table 2).
Similar mean estrone conjugates baseline concentrations
were observed across all groups, ranging from 237.7 to
343.4 pg/mL. At days 1 and 14, the estrone conjugate concentrations ranged between approximately 100 to 400 pg/mL
in most women. No differences from placebo in any
estrone conjugate parameters were observed for any of the
TX-004HR doses, except for day 1 tmax for the 25-mg dose
(Table 2). Baseline-adjusted results for estrone and estrone
conjugates were similar to the unadjusted results (Supplemental Table S1, Supplemental Digital Content 1, http://links.
lww.com/MENO/A205).

1.9, 4.4, 0.6, and 10.2 nmol/L, respectively, for TX-004HR
4, 10, and 25 mg, and placebo.

Sex hormone binding globulin
Least square mean changes in SHBG from baseline to week
2 were: 3.0, 1.9, 2.2, and 2.1 nmol/L; and to week 12 were:

Mean Serum Estradiol Concentration (SE), pg/mL
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FIG. 2. Unadjusted mean serum estradiol concentrations TX-004HR
10 mg (n ¼ 19) versus placebo (n ¼ 17).

DISCUSSION
Vaginal administration of 4, 10, and 25 mg of TX-004HR
resulted in negligible to very low systemic absorption of
estradiol in healthy postmenopausal women with VVA while
providing VVA efficacy and symptom relief as early as week
2. In the primary REJOICE study, TX-004HR at 4, 10, and
25 mg demonstrated robust efficacy for improvement in the
percentage of superficial and parabasal cells, vaginal pH, and
severity of dyspareunia as early as 2 weeks, with continued
efficacy up to 12 weeks.8 Also, 4, 10, and 25 mg TX-004HR,
when compared with placebo, significantly improved vaginal
dryness and vulvar and/or vaginal itching or irritation.8
The most relevant pharmacokinetic parameters in this study
are Cavg, which measures the average plasma concentration
of TX-004HR during a dosing interval, and AUC, which
measures the overall systemic exposure of TX-004HR. Both
estradiol Cavg and AUC were not statistically different for
4 and 10 mg TX-004HR compared with placebo. Estradiol
AUC and Cavg for the 25-mg dose were significantly higher
than with the placebo on days 1 and 14, but average levels of
estradiol were very low and remained within the normal
postmenopausal range (30 pg/mL).9 An initial increase in
estradiol absorption followed by a decrease over time has been
commonly observed in PK studies of vaginal estrogens,10-12
and may be due to higher absorption through thin, atrophic
vaginal tissues early in treatment, and then less absorption with
improvement in vaginal maturation later in treatment.13 These
data demonstrated that TX-004HR provided a novel delivery
system with negligible systemic estradiol absorption.
Overall, there did not appear to be any estradiol accumulation with any doses of TX-004HR as endogenous values
were observed at day 84. In addition, no notable changes in
estrone conjugates or SHBG were observed with TX-004HR,
consistent with the negligible to very low absorption of
estradiol with its administration. Vaginal, low-dose estrogen
therapies are intended to effectively treat symptoms of VVA
Menopause, Vol. 24, No. 5, 2017
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TABLE 2. Unadjusted pharmacokinetic parameters (mean  SD)
TX-004HR

Estradiol
Day 1
AUC, pgh/mL
Cmax, pg/mL
Cavg, pg/mL
Cmin, pg/mL
tmax, h
Day 14
AUC, pgh/mL
Cmax, pg/mL
Cavg, pg/mL
Cmin, pg/mL
tmax, h
Estrone
Day 1
AUC, pgh/mL
Cmax, pg/mL
Cavg, pg/mL
Cmin, pg/mL
tmax, h
Day 14
AUC, pgh/mL
Cmax, pg/mL
Cavg, pg/mL
Cmin, pg/mL
tmax, h
Estrone conjugates
Day 1
AUC, pgh/mL
Cmax, pg/mL
Cavg, pg/mL
Cmin, pg/mL
tmax, h
Day 14
AUC, pgh/mL
Cmax, pg/mL
Cavg, pg/mL
Cmin, pg/mL
t, h

4 mg (n ¼ 18)

10 mg (n ¼ 19)

25 mg (n ¼ 18)

Placebo (n ¼ 17)

91.7  37.9
6.5  2.1
3.9  1.5
3.3  1.3
7.0  9.4

138.2  75.2
10.9  5.0b
5.8  3.1
4.4  2.7
6.1  8.0

217.4  99.0a
29.8  17.5c
9.1  4.1a
3.5  1.7
4.6  7.1

116.6  77.3
6.6  4.9
4.9  3.2
3.9  2.6
8.6  6.7

87.2  42.8
4.8  2.3
3.6  1.8
3.2  1.5
9.3  8.9

110.1  54.6
7.3  2.4
4.6  2.3
3.6  1.9
4.0  2.6a

171.6  80.1b
15.7  7.6c
7.1  3.3b
4.3  2.5
2.7  1.9c

104.2  66.4
5.5  3.4
4.3  2.8
3. 4  2.1
7.2  3.0

290.2  123.7b
15.8  6.1b
13.0  4.7b
11.6  4.3
14.1  9.4

462.7  195.6
23.5  9.9
19.3  8.2
17.1  7.5
11.9  9.8

419.1  147.9
21.9  7.7
17.5  6.2
15.0  5.8
9.1  7.4

467.9  278.8
25.7  18.4
19.5  11.6
16.5  10.0
12.1  9.4

326.6  114.1
16.0  5.5b
13.6  4.8
12.2  4.4
10.9  9.0

464.1  243.9
23.9  13.5
19.3  10.2
17.4  8.5
10.4  8.9

428.7  161.7
22.4  8.9
17.9  6.7
16.0  6.1
6.3  6.9b

426.8  180.7
22.8  10.9
17.8  7.5
14.3  7.1
12.2  9.2

5078  3798
273.1  196.4
215.9  154.8
178.3  128.7
10.9  8.7

5932  4210
329.4  226.6
247.2  175.4
208.7  137.0
9.2  9.3

9126  9186
542.1  475.5
380.3  382.8
288.0  311.3
5.4  2.6a

5638  3151
309.8  146.1
244.6  128.1
207.6  146.0
13.1  9.7

5173  3383
289.0  183.8
215.5  141.0
174.3  121.8
8.4  7.8

8978  9811
511.7  568.8
374.1  408.8
271.6  285.0
9.0  8.6

9930  11710
579.5  610.1
413.8  488.0
303.7  380.6
5.9  2.9

6275  3398
343.6  182.2
261.5  141.6
207. 8  111.5
8.1  6.8

Data are unadjusted for baseline and represented as mean  SD.
AUC, area under the serum concentration-time curve.
a
P < 0.01, bP < 0.05, cP < 0.0001 versus placebo using t tests.

with negligible systemic absorption of estrogen.1 However,
whereas current products limit systemic estrogen absorption,
they do not completely eliminate it, as elevated circulating
estrogen levels with some vaginal products have been shown
in PK studies.12,14 A rapid rise in estradiol concentrations was
found with a 25-mg vaginal estradiol tablet within 8 hours of
administration, which remained above normal postmenopausal levels for 2 weeks.12 Vaginal creams have also been
associated with adverse effects such as breast pain and uterine
bleeding, which are indicative of systemic exposure to estradiol.15 Similarly, a low-dose vaginal estrogen ring, which
releases 7.5 mg/d, showed a peak estradiol concentration of
60 pg/mL at 2 hours; although estradiol rapidly declined to be
within normal postmenopausal estrogen levels, decreases in
the rate of bone resorption and in low-density lipoprotein
cholesterol levels were observed, suggesting systemic estrogenic effects.16 Further, a PK study using a validated, accurate, and sensitive MS assay showed that serum estradiol
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increased by at least five-fold with a vaginal estradiol tablet
and a conjugated estrogens cream after 1 week of daily
treatment.14 Advantages of limiting estrogen exposure to
the vagina as opposed to systemic estrogen include decreased
risk of systemic adverse effects and endometrial stimulation.17 In the current study, TX-004HR administration
resulted in estradiol levels that remained well within the
normal postmenopausal range, and the reported adverse
events were not indicative of estrogen systemic exposure.
The PK profile for TX-004HR (ie, negligible to very low
systemic absorption) could allow clinicians to follow the
recommendation of The North American Menopause Society
to use low-dose vaginal estrogens without a concomitant
progestin.1 Furthermore, the lack of systemic absorption with
the use of TX-004HR is aligned with the American Congress
of Obstetricians and Gynecologists’ recommendation for the
use of low-dose vaginal estrogens for treating vaginal symptoms in survivors of estrogen-dependent breast cancer.3
ß 2016 The Author(s)
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Although any woman meeting entry criteria was eligible for
enrollment into the clinical trial, the study population was
predominately white, which may limit the generalizability of
the study results to the general population.
CONCLUSIONS
Vaginal administration of TX-004HR resulted in negligible
to very low systemic absorption of estradiol with no drug
accumulation. PK parameters with TX-004HR at 4 and 10 mg
were similar to placebo for key estradiol parameters. Whereas
there were minor increases in these estradiol parameters with
25 mg TX-004HR, serum concentrations remained within the
normal postmenopausal range. This PK substudy, in conjunction with the efficacy results of the main study, demonstrates
that TX-004HR provides local estrogenic benefits with minimal increases in estrogen systemic exposure.
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